Please assess the completion status of the following clinical trial:

Trial Title: Dose Range Study of CD5789 in Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participant, 12 to 35 years old with the following characteristics:~* Facial acne severity grade of the following:~  * Stratum 1: IGA score of 3 or 4~ * Stratum 2: IGA score of 4~ * Stratum 3: IGA score of 3 or 4~* A minimum of 30 non-inflammatory lesions and fulfills the criteria of one of the following strata:~  * Stratum 1: A minimum of 20 but not more than 40 inflammatory lesions, and a maximum of one nodule on the face.~ * Stratum 2: More than 40 inflammatory lesions, and up to four nodules on the face.~ * Stratum 3: Participants of Japanese origin with at least 20 inflammatory lesions and up to four nodules on the face.~    * Note: Participants of Japanese origin will not be included in Stratum 1 or Stratum 2. Japanese origin is defined as all four grandparents were born in Japan.~Exclusion Criteria:~* The presence of severe forms of acne (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug-induced acne, etc.)~* Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results and/or put the participant at significant risk (according to the Investigator's judgment) if the participant participates in the clinical trial.~* Known or suspected allergies or sensitivities to any components of any of the study drugs.~* Current participation in any other clinical trial of a drug or device OR past participation within the 30 days prior to the Baseline visit.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- CD5789 25 mcg/g Cream (Type: EXPERIMENTAL): Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
- CD5789 50 mcg/g Cream (Type: EXPERIMENTAL): Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
- CD5789 100 mcg/g Cream (Type: ACTIVE_COMPARATOR): Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
- Tazarotene 0.1% Gel (Type: PLACEBO_COMPARATOR): Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
- Vehicle Cream (Type: EXPERIMENTAL): Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).